Abstract
Chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and asthma, are characterized by long-term inflammation that significantly impacts patients' quality of life. Conventional drug therapies often face challenges related to efficacy, side effects, and patient compliance. In response, recent advancements in biopharmaceutical drug delivery systems have aimed at improving the targeted delivery, bioavailability, and therapeutic efficacy of drugs. This article reviews the latest developments in drug delivery technologies for chronic inflammatory diseases, including nanoparticles, liposomes, biologics, and gene therapy. Additionally, it discusses the future potential of these systems in transforming the treatment landscape for chronic inflammation.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Dr. Muhammad Usman Arshad (Author)